|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.840 USD | -4.70% |
|
+2.53% | -21.33% |
| 07-28 | Altimmune, Inc. - Special Call | |
| 07-28 | Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bearish | Bearish |
| Resistance | 3.16 | 3.56 | 3.83 |
| Spread/Res. | -10.13% | -20.22% | -25.85% |
| Spread/Supp. | +2.53% | +9.65% | +8.81% |
| Support | 2.77 | 2.59 | 2.61 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ALT Stock
- Charts Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
